INTELLIGENT BIO SOLUTIONS INC. Cost of Revenue
INTELLIGENT BIO SOLUTIONS INC. (INBS) reported Cost of Revenue of $2.17 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-19.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-19
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for the quarter ending 2026-06-30 was $609.22K, a 19.85% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for the quarter ending 2026-03-31 was $525.42K, a 35.59% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for the quarter ending 2025-12-31 was $437.04K, a 13.70% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for the quarter ending 2025-09-30 was $593.51K, a 12.94% increase year-over-year.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for fiscal 2026 was $2.17M, a 19.91% increase from fiscal 2025.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for fiscal 2025 was $1.81M, a 7.09% increase from fiscal 2024.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for fiscal 2024 was $1.69M, a 81.27% increase from fiscal 2023.
- INTELLIGENT BIO SOLUTIONS INC. cost of revenue for fiscal 2023 was $930.20K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $609.22K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $1.13M derived: sum of 2 quarters · filed 2026-08-19 | $1.57M derived: sum of 3 quarters · filed 2026-08-19 | $2.17M 10-K · filed 2026-08-19 |
| 2026-03-31 | $525.42K 10-Q · filed 2026-05-13 | $962.46K derived: sum of 2 quarters · filed 2026-05-13 | $1.56M 10-Q · filed 2026-05-13 | $2.06M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $437.04K 10-Q · filed 2026-02-12 | $1.03M 10-Q · filed 2026-02-12 | $1.54M derived: sum of 3 quarters · filed 2026-08-19 | $1.93M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $593.51K 10-Q · filed 2025-11-12 | $1.10M derived: sum of 2 quarters · filed 2026-08-19 | $1.49M derived: sum of 3 quarters · filed 2026-08-19 | $1.87M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $508.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-19 | $895.81K derived: sum of 2 quarters · filed 2026-08-19 | $1.28M derived: sum of 3 quarters · filed 2026-08-19 | $1.81M 10-K · filed 2026-08-19 |
| 2025-03-31 | $387.50K 10-Q · filed 2026-05-13 | $771.88K derived: sum of 2 quarters · filed 2026-05-13 | $1.30M 10-Q · filed 2026-05-13 | $1.21M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $384.38K 10-Q · filed 2026-02-12 | $909.87K 10-Q · filed 2026-02-12 | $822.13K derived: sum of 3 quarters · filed 2026-02-12 | $1.47M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $525.49K 10-Q · filed 2025-11-12 | $437.75K derived: sum of 2 quarters · filed 2025-11-12 | $1.08M derived: sum of 3 quarters · filed 2025-11-12 | $1.65M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$87.73K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-15 | $557.58K derived: sum of 2 quarters · filed 2025-08-15 | $1.12M derived: sum of 3 quarters · filed 2025-08-15 | $1.69M 10-K · filed 2025-08-15 |
| 2024-03-31 | $645.31K 10-Q · filed 2025-05-13 | $1.21M derived: sum of 2 quarters · filed 2025-05-13 | $1.77M 10-Q · filed 2025-05-13 | $2.17M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $564.82K 10-Q · filed 2025-02-13 | $1.13M 10-Q · filed 2025-02-13 | $1.52M derived: sum of 3 quarters · filed 2025-02-13 | $1.95M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $563.76K 10-Q · filed 2024-11-07 | $957.32K derived: sum of 2 quarters · filed 2024-11-07 | $1.38M derived: sum of 3 quarters · filed 2024-11-07 | $1.49M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $393.56K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-18 | $817.57K derived: sum of 2 quarters · filed 2024-09-18 | $930.20K derived: sum of 3 quarters · filed 2024-09-18 | $930.20K 10-K · filed 2024-09-18 |
| 2023-03-31 | $424.01K 10-Q · filed 2024-05-08 | $536.64K derived: sum of 2 quarters · filed 2024-05-08 | $536.64K 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $112.64K 10-Q · filed 2024-02-09 | $112.64K 10-Q · filed 2024-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |